As 2026 nears, operator enthusiasm for open RAN is weakening even as many continue to pursue long-term plans, GSMA said.

The Journal of the San Juan Islands relies on subscription revenue to provide local content for our readers.

Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...